Good examples are epidermal growth factor receptor (EGFR) mutation for predicting the effectiveness of EGFR tyrosine kinase inhibitors (TKIs) in lung adenocarcinoma [3], as well as KRAS mutation for predicting the unresponsiveness of EGFR monoclonal antibody in colorectal cancer (CRC) [4]. This evidence concerns the gene EGFR and lung adenocarcinoma.